French tech Keen Eye to bring its AI to Iris Pharma in partnership deal

blue eye
Keen Eye will bring its artificial intelligence applications to CRO Iris Pharma as part of a new collaboration. (Pixabay)

French tech company Keen Eye will bring its artificial intelligence applications to Iris Pharma, a CRO focused on ophthalmology, as part of a new collaboration.

Under the agreement, Keen Eye’s AI is expected to make assays much faster and more reliable and efficient. Iris Pharma offers preclinical and clinical services for drug and medical device development.

Financial terms of the deal weren’t disclosed.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“The advanced AI technology of Keen Eye allows us to optimize the performance of the bioimaging analysis during the preclinical ophthalmic drug development, and in the future for clinical development,” Yann Quentric, Iris Pharma’s president, said in a statement.

“We are expecting to contribute to the most challenging image-based assays to better fight eye diseases,” Keen Eye’s founder and chief executive, Sylvain Berlemont, added.

Iris, which is also headquartered in France, is a full-service research organization with a long history of helping to get ocular drugs and devices onto the market.

Suggested Articles

Qiagen is collaborating with Ares Genetics to develop new bioinformatics and assay solutions for research targeting antibiotic-resistant bacteria.

STA Pharmaceutical has signed an exclusive technology and marketing deal with Swiss biotech BioLingus.

Clinerion is partnering with Citeline to give clinical researchers a more comprehensive approach to making evidence-based decisions.